share_log

Wedbush Analyst Assumes Coverage of Neutral-Rated Sangamo Therapeutics, Adjusts Price Target to $5 From $10, Notes 'Uncertainty Around' SAR445136 Path Forward in Sickle Cell Disease

Wedbush Analyst Assumes Coverage of Neutral-Rated Sangamo Therapeutics, Adjusts Price Target to $5 From $10, Notes 'Uncertainty Around' SAR445136 Path Forward in Sickle Cell Disease

韋德布什分析師假設中性評級的Sangamo治療公司的報道，將目標價從10美元調整為5美元，注意到SAR445136在鐮狀細胞病的前進路徑的不確定性
MT Newswires ·  2022/06/13 19:00

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論